Donor aortic graft improves reconstruction after partial laryngectomy

May 21, 2012

Massachusetts General Hospital (MGH) surgeons have developed a new technique for reconstructing the larynx after surgery for advanced cancer. In the May Annals of Otology, Rhinology and Laryngology, they describe how this approach – which uses cryopreserved aortas from deceased donors to replace removed larynx tissue – allowed patients to avoid a permanent tracheotomy and maintain voice and swallowing function with no need for immunosuppressive medications. The pioneering surgery was a collaborative effort between Steven Zeitels, MD, director of the MGH Center for Laryngeal Surgery, and John Wain, MD, surgical director of the MGH Lung Transplantation Service.

"Without this new reconstructive technique, most of these would have required a total laryngectomy," says Zeitels, corresponding author of the report. "I don't believe anything like this has been achieved before – especially for cancer reconstruction in patients whose tumors recurred after radiotherapy."

Although small laryngeal tumors can be successfully removed through minimally invasive laser surgery or treated with radiation, advanced tumors require more invasive procedures to remove the affected area, especially when chemotherapy and radiation have failed as initial treatment. In these situations, problems with the healing of tissues previously exposed to radiation and the lack of reliable reconstructive techniques have meant that a majority of patients having partial laryngectomy still needed a permanent tracheotomy – an opening through the neck and into the trachea – resulting in substantial voice and swallowing dysfunction. Since the quality of life would probably be better with removal of the entire larynx, patients and their surgeons often chose a total laryngectomy.

To address the reconstructive limitations of partial laryngectomy, Zeitels and Wain developed an approach using the body's largest blood vessel, the aorta, to reconstruct the larynx. The MGH surgeons first used a previously frozen aortic graft for reconstruction after partial laryngectomy for recurrent in 2009. Over the next two years, they performed the procedure on 15 patients, 8 of whom had previously received radiation therapy. All of these procedures were performed in one operation, combining both the tumor removal and reconstruction at the same time, and no immunosuppressive medications were needed.

Of that initial group of patients, all were able to have their postoperative tracheotomy tubes removed and resume breathing normally. All resumed speaking without the need for assistive devices, although their vocal quality depended on how much tissue had been removed, and all but one recovered and maintained swallowing function. Two patients had recurrence of their advanced tumors that required subsequent total laryngectomy. No stents were needed to keep patients' airways open, unlike in pilot trials using similar aortic grafts to reconstruct the trachea, which have had limited success.

"The shape of the aorta, which approximates that of the removed laryngeal tissue, and its ability to serve as a surface for healing within the airway are unique characteristics of these grafts that other forms of reconstruction do not provide," says Wain.

Zeitels adds, "The success of this procedure is remarkable, since the aortic tissue has held up extremely well against the stresses of a non-sterile environment, exposure to refluxing stomach fluids and the mechanical forces of swallowing and coughing. Given the success in this extremely challenging surgical scenario, it's likely that there will be many other uses for cryopreserved vascular grafts as supportive structures and tissue patches for surgery in other parts of the body."

Explore further: Robotic surgery effective for removing hard-to-reach throat cancer

Related Stories

Robotic surgery effective for removing hard-to-reach throat cancer

April 29, 2011
Robotic surgery has become a mainstream tool for removing an ever-increasing variety of head and neck tumors. Now, a team of head and neck surgeons from Mayo Clinic has found robotic surgery can treat cancer in the narrow, ...

New surgical technique for removing inoperable tumors of the abdomen

May 1, 2012
Abdominal tumors involving both roots of the celiac and superior mesenteric artery (SMA) are deemed unresectable by conventional surgical methods, as removal would cause necrosis of the organs that are supplied by those blood ...

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.